Chapter title |
Further Delineation of the ALG9-CDG Phenotype.
|
---|---|
Chapter number | 504 |
Book title |
JIMD Reports, Volume 27
|
Published in |
JIMD Reports, October 2015
|
DOI | 10.1007/8904_2015_504 |
Pubmed ID | |
Book ISBNs |
978-3-66-250408-6, 978-3-66-250409-3
|
Authors |
AlSubhi, Sarah, AlHashem, Amal, AlAzami, Anas, Tlili, Kalthoum, AlShahwan, Saad, Lefeber, Dirk, Alkuraya, Fowzan S, Tabarki, Brahim, Sarah AlSubhi, Amal AlHashem, Anas AlAzami, Kalthoum Tlili, Saad AlShahwan, Dirk Lefeber, Fowzan S. Alkuraya, Brahim Tabarki |
Abstract |
ALG9-CDG is one of the less frequently reported types of CDG. Here, we summarize the features of six patients with ALG9-CDG reported in the literature and report the features of four additional patients. The patients presented with drug-resistant infantile epilepsy, hypotonia, dysmorphic features, failure to thrive, global developmental disability, and skeletal dysplasia. One patient presented with nonimmune hydrops fetalis. A brain MRI revealed global atrophy with delayed myelination. Exome sequencing identified a novel homozygous mutation c.1075G>A, p.E359K of the ALG9 gene. The results of our analysis of these patients expand the knowledge of ALG9-CDG phenotype. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 2 | 18% |
Student > Master | 2 | 18% |
Student > Ph. D. Student | 1 | 9% |
Unspecified | 1 | 9% |
Researcher | 1 | 9% |
Other | 1 | 9% |
Unknown | 3 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 18% |
Agricultural and Biological Sciences | 2 | 18% |
Unspecified | 1 | 9% |
Medicine and Dentistry | 1 | 9% |
Neuroscience | 1 | 9% |
Other | 1 | 9% |
Unknown | 3 | 27% |